Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Princeton, NJ, US. The stock last traded at $2.11, down 0.47% on the session, giving a market capitalisation of $34.3M. On trailing twelve-month figures it carries a trailing P/E of -3.80, a net margin of 0.0%. Its beta of 0.37 implies it has historically moved less than the broad market.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Grace Therapeutics, Inc. is most often compared with the following Healthcare names: